Trial · NCT05131477
Participant flow126
How many started, completed or left each group, period by period.
21 to 40 of 126
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| PART 1 | Randomized and Treated | Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2) | 0 | |
| PART 1 | Randomized and Treated | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | 0 | |
| PART 1 | Randomized and Treated | Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2) | 0 | |
| PART 1 | Randomized and Treated | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | 0 | |
| PART 1 | Randomized and Treated | Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2) | 0 | |
| PART 1 | Randomized and Treated | 62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2) | 0 | |
| PART 1 | Randomized and Treated | Placebo Re-randomized From the 62.5 mg Arm (Part 2) | 0 | |
| PART 1 | Randomized and Treated | Placebo (Part 2) Continued From Part 1 Placebo | 0 | |
| PART 1 | Re-randomized at Week 24 | 250 mg (500 mg LD) KY1005 (Part 1) | 47 | |
| PART 1 | Re-randomized at Week 24 | 250 mg (no LD) KY1005 (Part 1) | 40 | |
| PART 1 | Re-randomized at Week 24 | 125 mg KY1005 (Part 1) | 45 | |
| PART 1 | Re-randomized at Week 24 | 62.5 mg KY1005 (Part 1) | 42 | |
| PART 1 | Re-randomized at Week 24 | Placebo (Part 1) | 16 | |
| PART 1 | Re-randomized at Week 24 | 250 mg KY1005 Re-Randomized From the 250 mg (LD) Arm (Part 2) | 0 | |
| PART 1 | Re-randomized at Week 24 | Placebo Re-Randomized From the 250 mg (LD) Arm (Part 2) | 0 | |
| PART 1 | Re-randomized at Week 24 | 250 mg KY1005 Re-randomized From the 250 mg (No LD) Arm (Part 2) | 0 | |
| PART 1 | Re-randomized at Week 24 | Placebo Re-Randomized From the 250 mg (No LD) Arm (Part 2) | 0 | |
| PART 1 | Re-randomized at Week 24 | 125 mg KY1005 Re-randomized From the 125 mg Arm (Part 2) | 0 | |
| PART 1 | Re-randomized at Week 24 | Placebo Re-randomized From the 125 mg KY1005 Arm (Part 2) | 0 | |
| PART 1 | Re-randomized at Week 24 | 62.5 mg Re-Randomized From the 62.5 mg KY1005 Arm (Part 2) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05131477/flow?page=2